U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926894) titled 'R-MVST Cells for Treatment of Viral Infections in Children and Young Adults' on April 08.
Brief Summary: The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxici...